LMNX @ $20.80 (Luminex) develops biological testing systems to perform genetic analysis for the development and identification of new drugs and genes. Revenues have increased 28%, 32%, 55% and 51% over the last four quarters. The stock recently cleared the $18 resistance level and volume has steadily increased over the last couple of months. We are establishing a 1/4 position here and will enter the second 1/4 at $19. The remaining half will be bought around $18 or a test of its rising 50 day moving average. Our stop loss will be set at the 200 day moving average.

Stocks Under $10

AEHR @ $8.65 (Aehr Test Systems) manufactures wafer test and burn-in systems used to analyze memory and logic IC's for the semiconductor industry. Revenues have increased 18%, 7%, 55% and 90% over the last four quarters. Earnings have grown 86%, 33%, 90% and 400% over the same time frame and are expected to increase 116% this year and another 44% in 2009 to $1.18 a share. This stock is cheap and not followed by anyone on Wall Street. We are establishing half a position here and will enter the remaining half on a pull back to $7.50. We feel this is at least a $20 stock in a year or two and are treating it accordingly by adding it to the Stock Playbook 100. Just an FYI, we didn't list a stop loss level because we plan to accumulate more if we see the $6 level. Every once in awhile, we break our own rules and fall in love with a stock, which you should never do. We won't consider bailing on this stock until we see a move below $5.25 and we'll re-evaluate there depending on volume.

Options

For the options traders, we feel SLB and MOS are both ready to roll over and have a defined downside.

We like the SDB PT (Schlumberger April $100 Put) with a stop set on a move above $93 by SLB.

We also bought the MTJ PE (Mosaic April $125 Put) with a stop set on a move above $110 by MOS.

This newsletter has been sent to you for informative purposes only and in no event should be construed as a representation by The Stock Playbook or its employees as an offer to sell or solicitation of an offer to buy any securities. The factual information given is taken from sources we believe to be reliable, but is not guaranteed as to its accuracy or completeness. The opinions expressed should be given only such weight as opinions warrant.  employees and/or family members may have a position in the securities mentioned and may make purchase and/or sales of such securities from time to time in the open market or otherwise Recipients of The Stock Playbook prohibited from, directly or indirectly, distributing, forwarding , plagiarizing or copying any part of this message without expressed written consent from The Stock Playbook. Some content may have been based, at least in part, on material gathered from Investor's Business Daily ® and/or YAHOO!®